Science News
from research organizations

Neuroimaging may shed light on how Alzheimer's disease develops

Date:
January 14, 2010
Source:
IOS Press
Summary:
Current Alzheimer's disease research indicates that accumulation of amyloid-beta (AB) protein plaques in the brain is central to the development of AD. While previously presence of these plaques could only be confirmed at autopsy. Positron emission tomography provides researchers with an opportunity to test the amyloid hypothesis as it occurs in living patients. A new study summarizes the results of experiments using the AB tracer Pittsburgh Compound-B.
Share:
       
FULL STORY

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD. Unfortunately, presence of these plaques is typically confirmed only at autopsy. In a special issue of the journal Behavioural Neurology, researchers review the evidence that Positron emission tomography (PET) can image these plaques during life. This exciting new technique provides researchers with an opportunity to test the amyloid hypothesis as it occurs in living patients.

In a review article with over 100 references, Dr. Gil Rabinovici and Dr. William Jagust from the University of California, San Francisco and Berkeley, summarize the results of experiments from their laboratories and others using the Aβ tracer Pittsburgh Compound-B (PIB). This compound binds to Aβ protein and allows the mapping of plaques in the brains of AD and non-AD volunteer subjects.

They report that PIB-PET can detect Aβ deposits in a significant proportion of cognitively normal older subjects and that these deposits are associated with brain atrophy even in the absence of cognitive symptoms. By the time patients develop mild cognitive impairment (MCI) amyloid load in the brain appears to have reached a plateau. As patients progress to dementia, neurodegeneration and cognitive decline proceed independently of further amyloid accumulation.

The authors interpret these results as consistent with a model in which amyloid deposition plays a critical early role on the path to AD, beginning years before onset of symptoms and triggering a series of events which ultimately leads to cognitive decline and dementia.

While the use of PIB-PET is currently limited to research centers because of the compound's very short radioactive half-life (20 minutes), new amyloid imaging agents with longer half-lives are under development for more widespread use. Amyloid imaging is already playing an important role in the development of amyloid-based therapies for AD, and Dr. Rabinovici and Dr. Jagust speculate that in the future amyloid imaging will assist clinicians in identifying patients with mild or atypical symptoms who may be candidates for anti-amyloid treatments.

Writing in the article, the authors state, "PIB-PET has provided us with our first in vivo glance at the dynamic relationship between amyloid deposition, clinical symptoms, and structural and functional changes in the brain in the continuum between normal aging and AD…In the future, Aβ imaging will likely supplement clinical evaluation in selecting patients for anti-amyloid therapies both during drug development and in the clinic."


Story Source:

The above post is reprinted from materials provided by IOS Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. G.D. Rabinovici and W.J. Jagust. Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behavioural Neurology, 2009; Vol. 21, Issues 1-2

Cite This Page:

IOS Press. "Neuroimaging may shed light on how Alzheimer's disease develops." ScienceDaily. ScienceDaily, 14 January 2010. <www.sciencedaily.com/releases/2010/01/100111102523.htm>.
IOS Press. (2010, January 14). Neuroimaging may shed light on how Alzheimer's disease develops. ScienceDaily. Retrieved August 4, 2015 from www.sciencedaily.com/releases/2010/01/100111102523.htm
IOS Press. "Neuroimaging may shed light on how Alzheimer's disease develops." ScienceDaily. www.sciencedaily.com/releases/2010/01/100111102523.htm (accessed August 4, 2015).

Share This Page: